CagriSema May Not Be Enough to Restore Novo Nordisk’s Obesity Lead
Novo Nordisk did not lose momentum because CagriSema is a weak drug. That is too simple. The sharper problem is that CagriSema is being asked to solve a structural challenge: Lilly has already taken the efficacy lead with tirzepatide, is pushing the ceiling higher with retatrutide, and is building a broader obesity portfolio while Novo remains heavily tied to semaglutide….
Trending News
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks
The stock market is now looking at the US-Israel-Iran conflict through a sharper…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains
The US-Israel-Iran war is affecting pharma stocks, drug supply chains, logistics costs, cold-chain…
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy…
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion | Witfire Elite View…
Editorial picks
CagriSema May Not Be Enough to Restore Novo Nordisk’s Obesity Lead
India’s Generic Ozempic Boom Is a Margin Trap—and the Price Collapse It Started Has Now Reached the US
Eli Lilly Retatrutide Phase 3 Results at ADA 2026
FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug
CagriSema May Not Be Enough to Restore Novo Nordisk’s Obesity Lead
Novo Nordisk did not lose momentum because CagriSema is a weak drug. That is too simple. The sharper problem is that CagriSema is being asked to solve a structural challenge: Lilly has already taken the efficacy lead with tirzepatide, is pushing the ceiling higher with retatrutide, and is building a…
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion
IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections
India’s Generic Ozempic Boom Is a Margin Trap—and the Price Collapse It Started Has Now Reached the US
Categories
Investments
business news
Entrepreneurship
Startups
2026
INSIGHTS FOR THE NEW PHARMA LEADERS
Witfire Elite brings focused perspectives on pharma growth, innovation, manufacturing, startups, and executive strategy.
Around The World
Eli Lilly Retatrutide Phase 3 Results at ADA 2026
Eli Lilly Retatrutide Phase 3: 28.3% Weight Loss Pushes Obesity Into a Portfolio War | Witfire Elite View Witfire Elite Pharma News Investments Stock Market Breaking Analysis 28.3 Pharma Market Case Study · Witfire Elite View Eli Lilly Retatrutide Phase 3 Results A 28.3% average weight loss at 80 weeks is the headline. But the real story is that Lilly…
Pharma News
CagriSema May Not Be Enough to Restore Novo Nordisk’s Obesity Lead
Novo Nordisk did not lose momentum because CagriSema is a weak drug. That is too simple. The sharper…
India’s Generic Ozempic Boom Is a Margin Trap—and the Price Collapse It Started Has Now Reached the US
Witfire Elite View · Pharma Market Case Study · Updated 12 June 2026 The cheapest semaglutide in the…
Eli Lilly Retatrutide Phase 3 Results at ADA 2026
Eli Lilly Retatrutide Phase 3: 28.3% Weight Loss Pushes Obesity Into a Portfolio War | Witfire Elite View…